[go: up one dir, main page]

EP4358955A4 - Compositions et méthodes de traitement du syndrome de gorlin - Google Patents

Compositions et méthodes de traitement du syndrome de gorlin

Info

Publication number
EP4358955A4
EP4358955A4 EP22829156.3A EP22829156A EP4358955A4 EP 4358955 A4 EP4358955 A4 EP 4358955A4 EP 22829156 A EP22829156 A EP 22829156A EP 4358955 A4 EP4358955 A4 EP 4358955A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
gorlin syndrome
gorlin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP22829156.3A
Other languages
German (de)
English (en)
Other versions
EP4358955A1 (fr
Inventor
Braham Shroot
Kathleen GOIN
Wesley Harton KAUPINEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palvella Therapeutics Inc
Original Assignee
Palvella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palvella Therapeutics Inc filed Critical Palvella Therapeutics Inc
Publication of EP4358955A1 publication Critical patent/EP4358955A1/fr
Publication of EP4358955A4 publication Critical patent/EP4358955A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP22829156.3A 2021-06-21 2022-06-21 Compositions et méthodes de traitement du syndrome de gorlin Withdrawn EP4358955A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163212936P 2021-06-21 2021-06-21
US202263364902P 2022-05-18 2022-05-18
PCT/US2022/034347 WO2022271702A1 (fr) 2021-06-21 2022-06-21 Compositions et méthodes de traitement du syndrome de gorlin

Publications (2)

Publication Number Publication Date
EP4358955A1 EP4358955A1 (fr) 2024-05-01
EP4358955A4 true EP4358955A4 (fr) 2025-01-08

Family

ID=84544918

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22829156.3A Withdrawn EP4358955A4 (fr) 2021-06-21 2022-06-21 Compositions et méthodes de traitement du syndrome de gorlin

Country Status (5)

Country Link
US (1) US20240293378A1 (fr)
EP (1) EP4358955A4 (fr)
JP (1) JP2024522808A (fr)
AU (1) AU2022300265A1 (fr)
WO (1) WO2022271702A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267869B2 (en) 2017-01-06 2023-10-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020010073A1 (fr) * 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
US20200261427A1 (en) * 2019-02-20 2020-08-20 Al Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411938B1 (fr) * 2001-07-02 2005-07-06 Tas, Sinan Utilisation de la cyclopamine pour la préparation d'un médicament pour le traitement du psoriasis
US7806924B2 (en) * 2004-02-18 2010-10-05 Cordis Corporation Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis
BRPI0607606B1 (pt) * 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
EP2650682A1 (fr) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Esters asymétriques d'acides gras utiles en tant que lubrifiants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020010073A1 (fr) * 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
US20200261427A1 (en) * 2019-02-20 2020-08-20 Al Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JULIE K. IWASAKI ET AL: "The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 66, no. 5, 1 May 2012 (2012-05-01), pages e167 - e178, XP055085189, ISSN: 0190-9622, DOI: 10.1016/j.jaad.2010.06.054 *
See also references of WO2022271702A1 *

Also Published As

Publication number Publication date
EP4358955A1 (fr) 2024-05-01
WO2022271702A1 (fr) 2022-12-29
JP2024522808A (ja) 2024-06-21
AU2022300265A1 (en) 2024-01-18
US20240293378A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
EP3920923A4 (fr) Agents thérapeutiques et méthodes de traitement
EP3983445A4 (fr) Compositions et méthodes de traitement du cancer
MA52790A (fr) Compositions et méthodes de traitement de la thrombopénie immune
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
EP3758714A4 (fr) Méthodes et compositions de traitement du syndrome d'angelman
EP4319751A4 (fr) Compositions thérapeutiques et méthodes de traitement de tumeurs
EP3658142A4 (fr) Compositions et méthodes de traitement de la galactosémie
EP4358955A4 (fr) Compositions et méthodes de traitement du syndrome de gorlin
EP3691649A4 (fr) Compositions et méthodes de traitement des plaies
EP4149547A4 (fr) Compositions et méthodes pour le traitement du cancer
PL4125843T3 (pl) Leczenie ciężkiego zespołu zapalnego
EP4308732A4 (fr) Méthodes de classification et de traitement de patients
EP4247362A4 (fr) Formulations et méthodes de traitement d?une surdose aigüe de cannabioïdes
EP4138879A4 (fr) Méthodes et compositions
EP4384220A4 (fr) Compositions et méthodes de traitement du cancer
EP4135760A4 (fr) Compositions et méthodes de traitement de la leucémie
EP4370118A4 (fr) Méthodes de traitement du syndrome néphrotique
EP4076669A4 (fr) Méthodes de traitement du glioblastome
EP3965799A4 (fr) Compositions et méthodes synergiques de traitement d'infections
EP4051308A4 (fr) Méthodes et compositions pour le traitement du syndrome de rett
EP3765012A4 (fr) Compositions et méthodes de traitement de la constipation sévère
EP3911358A4 (fr) Méthodes et compositions de traitement du cancer
EP3727436A4 (fr) Compositions et méthodes de traitement des syndromes d'ehlers-danlos
EP4232160A4 (fr) Compositions et méthodes de prévention et de traitement de coronavirus
MA48477A (fr) Compositions et méthodes de traitement de la dépression

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110069

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20241210

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20170101ALI20241204BHEP

Ipc: A61K 9/06 20060101ALI20241204BHEP

Ipc: A61P 17/00 20060101ALI20241204BHEP

Ipc: A61K 9/00 20060101ALI20241204BHEP

Ipc: A61P 35/00 20060101ALI20241204BHEP

Ipc: A61K 31/436 20060101AFI20241204BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20250528